Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

NCT01853319 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01853319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01853319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
July 24, 2013
Completion date
June 11, 2018
Enrollment
100 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms